AI to detect hidden spread in liver cancer from scans
Part of Cancer, Digestive system clinical trials.
This trial uses a computer program to help doctors find signs of microscopic tumor spread in blood vessels (microvascular invasion) from liver cancer images. It aims to improve treatment planning for patients who are having surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have been diagnosed with hepatocellular carcinoma (a type of liver cancer).
- You are eligible for surgery to remove the tumor or a liver transplant.
- You had a CT or MRI scan within one month before your surgery.
- The tumor has not spread to major blood vessels, bile ducts, or other parts of the body.
- You have not had any prior cancer treatment for this liver tumor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses artificial intelligence to help doctors better stage (classify the severity of) and plan treatment for hepatocellular carcinoma, a type of primary liver cancer. Researchers will collect your clinical information and imaging to see if AI can improve decision-making about your care.
This study tests whether an AI tool can help doctors read CT scans of the liver to find cancerous spots. If you have had a CT scan of your abdomen with specific timing, you might be able to join.
This study uses artificial intelligence (AI) to analyze your CT or MRI scans and help predict how well immunotherapy might work for your liver cancer. The goal is to find better ways to match you with the right treatment and improve your outcomes.
This study uses advanced imaging (ultrasound with contrast dye and MRI) combined with artificial intelligence to help doctors plan the best surgery for early-stage liver cancer. The goal is to improve treatment outcomes and help doctors choose between two surgical options: removing part of the liver or using heat to destroy the tumor.
This trial tests whether an artificial intelligence system can help detect liver cancer recurrence earlier after curative treatment, allowing for potentially curative salvage therapy. Participants who have undergone complete surgical removal or ablation of their first liver cancer will be monitored with AI-assisted imaging.
This study uses digital scans of your tumor tissue and CT/MRI images to build a computer model that helps predict whether you might need extra treatment (adjuvant therapy) after liver cancer surgery. The goal is to use your own tissue and scan data to personalize follow-up care.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.